or Try an Advanced Search...

    Technical Analysis for BCLI - Brainstorm Cell Therapeutics Inc.

    Grade Last Price % Change Price Change
    F 0.36 5.47% 0.02
    BCLI closed up 5.47 percent on Monday, July 1, 2024, on 61 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical BCLI trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Inside Day Range Contraction 5.47%
    Wide Bands Range Expansion 5.47%
    Gapped Up Strength 5.47%
    Down 3 Days in a Row Weakness 5.47%
    Oversold Stochastic Weakness 5.47%
    Fell Below 200 DMA Bearish -0.94%
    Wide Bands Range Expansion -0.94%
    Older End-of-Day Signals for BCLI ...

       Recent Intraday Alerts

    Alert Time
    Fell Below Previous Day's Low about 10 hours ago
    Down 1% about 10 hours ago
    Up 1% about 10 hours ago
    Gap Up Closed 3 days ago
    Gap Up Partially Closed 3 days ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    BCLI Chart by TradingView
    Basic chart:

    Profile

    Brainstorm Cell Therapeutics Inc. Description

    Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company's NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor and brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. It is developing NurOwn, an autologous adult stem cell product for the treatment of ALS. Brainstorm Cell Therapeutics Inc. also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics was founded in 2000 and is based in New York, New York.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biology Bone Stem Cell Parkinson's Disease Neurodegenerative Diseases Multiple Sclerosis Medical Research Amyotrophic Lateral Sclerosis Degenerative Disease Storm Bone Marrow Neurochemistry Neurodegenerative Disorders Induced Stem Cells Adult Stem Cell Cell Product Neuron Mesenchymal Stem Cell Cell Encapsulation Growth Factor Hadassah Medical Center Vascular Endothelial Growth Factor

    Is BCLI a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 27 BrainStorm Cell Therapeutics announces pricing of $4M registered direct offering
    Jun 27 BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
    Jun 26 BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial
    Jun 20 BrainStorm appoints Haro Hartounian as COO
    Jun 20 BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
    Jun 14 BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation
    May 20 BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn
    May 15 BrainStorm Cell Therapeutics GAAP EPS of -$0.05 beats by $0.02
    May 14 BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
    Apr 17 BrainStorm Cell Therapeutics promotes Bob Dagher to Chief Medical Officer
    See more BCLI news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.115
    52 Week Low 0.134
    Average Volume 665,976
    200-Day Moving Average 0.38
    50-Day Moving Average 0.46
    20-Day Moving Average 0.41
    10-Day Moving Average 0.38
    Average True Range 0.06
    RSI (14) 37.50
    ADX 20.94
    +DI 14.65
    -DI 24.47
    Chandelier Exit (Long, 3 ATRs) 0.38
    Chandelier Exit (Short, 3 ATRs) 0.50
    Upper Bollinger Bands 0.49
    Lower Bollinger Band 0.33
    Percent B (%b) 0.16
    BandWidth 39.00
    MACD Line -0.03
    MACD Signal Line -0.03
    MACD Histogram -0.0056
    Fundamentals Value
    Market Cap 17.49 Million
    Num Shares 49 Million
    EPS -0.42
    Price-to-Earnings (P/E) Ratio -0.85
    Price-to-Sales 0.00
    Price-to-Book 65.82
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.41
    Resistance 3 (R3) 0.41 0.39 0.40
    Resistance 2 (R2) 0.39 0.37 0.39 0.40
    Resistance 1 (R1) 0.37 0.36 0.38 0.37 0.40
    Pivot Point 0.35 0.35 0.35 0.35 0.35
    Support 1 (S1) 0.34 0.34 0.34 0.34 0.32
    Support 2 (S2) 0.32 0.33 0.32 0.32
    Support 3 (S3) 0.30 0.32 0.31
    Support 4 (S4) 0.30